NCT00418119

Brief Summary

Erythropoietin Treatment in Patients with systolic left ventricular dysfunction, mild anemia and normal renal function

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for phase_4 heart-failure

Timeline
Completed

Started Jan 2007

Shorter than P25 for phase_4 heart-failure

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

January 2, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 4, 2007

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2008

Completed
Last Updated

January 4, 2007

Status Verified

December 1, 2006

First QC Date

January 2, 2007

Last Update Submit

January 3, 2007

Conditions

Heart Failure

Interventions

erythropoietinDRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ischemic heart disease
  • Systolic lv dysfunction
  • Mild anemia
  • Normal renal function
  • Stable condition

You may not qualify if:

  • Pregnancy
  • Unstable condition
  • Under 18 years old

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cardiology Department, Rabin Medical Center

Petah Tikva, Petah Tikva, 49100, Israel

Location

MeSH Terms

Conditions

Heart Failure

Interventions

Erythropoietin

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Colony-Stimulating FactorsGlycoproteinsGlycoconjugatesCarbohydratesHematopoietic Cell Growth FactorsCytokinesIntercellular Signaling Peptides and ProteinsPeptidesAmino Acids, Peptides, and ProteinsProteinsBiological Factors

Study Officials

  • Tuvia Ben Gal, MD

    Cardiology Department Rabin medical Center

    PRINCIPAL INVESTIGATOR

  • Ofer Shpilberg, Prof.

    Hematology Department Rabin Medical Center

    STUDY DIRECTOR

  • Daniel Murninkas, MD

    Cardiology Department Rabin Medical Center

    STUDY DIRECTOR

Central Study Contacts

Tuvia Ben Gal, MD

CONTACT

972-522757616bengalt@clalit.org.il

Daniel Murninkas, MD

CONTACT

972-39376930murninkasd@clalit.org.il

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 2, 2007

First Posted

January 4, 2007

Study Start

January 1, 2007

Study Completion

January 1, 2008

Last Updated

January 4, 2007

Record last verified: 2006-12

Locations

IL(1)